Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results
in a clinical picture changes to a decrease of all signs of inflammation.
Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a
treatment with Apremilast seems to be an effective option.
In this study, treatment with Apremilast (Otezla®) will be performed in patients with acne
conglobata to observe its preliminary efficacy and safety in an open label, single-centre
proof of concept study design.
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Frank Behrens
Collaborators:
Celgene Dermatology Department University Hospital Frankfurt